Abstract
Multiple myeloma is a progressive and fatal disease characterized by the accumulation of malignant plasma cells in the bone marrow. Although the cause of myeloma remains unknown, interleukin 6 (IL-6) has been demonstrated to be a primary growth factor for malignant plasma cells in vitro [1, 2]. Elevated levels of IL-6 in myelomatous bone marrow and a direct correlation of IL-6 levels with disease severity suggest that IL-6 may be a crucial factor for tumor expansion in vivo as well [2, 3]. At the present time, it remains uncertain, however, as to whether paracrine or autocrine sources are responsible for the significant increases in IL-6 levels that occur during disease progression (reviewed in [4]).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332: 83–85
Zhang XG, Klein B, Bataille R (1989) Interleukin 6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood 74: 11–13
Bataille R, Jourdan M, Zhang XG, Klein B (1989) Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias. Blood 84: 2008–2011
Mandelli F, Awisati G, Tribalto M (1992) Biology and treatment of multiple myeloma. Curr Opin Oncology 4: 73–86
Muraguchi A, Hirano T, Tang B, Matsuda T, Horii Y, Nakajima K, Kishimoto T (1988) The essential role of B cell stimulating factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 167: 332–344
Roldin E, Brieva JA (1991) Terminal differentiation of human bone marrow cells capable of spontaneous and high-rate immunoglobulin secretion: Role of bone marrow stromal cells and interleukin 6. Eur J Immunol 21: 2671–2677
Splawski JB, McAnally LM, Lipsky PE (1990) IL-2 dependence of the promotion of human B cell differentiation by IL-6 (BSF-2). J Immunol 144: 562–569
Alderson MR, Pike BL (1989) Recombinant human interleukin 6 (B cell stimulatory factor 2) enhances immunoglobulin secretion by single murine haplen-specific B cells in the absence of cell division. Intl Immunol 1: 20–28
Beagley KW, Eldridge JH, Lee F, Kiyono H, Everson MP, Koopman WJ, Hirano T, Kishimoto T, McGhee JR (1989) Interleukins and IgA synthesis. Human and murine interleukin 6 induce high rate IgA secretion in IgA-committed B cells. J Exp Med 169: 2133–2148
Matthes T, Werner-Favre C, Tang H, Zhang X, Kindler V, Zubler RH (1993) Cytokine mRNA expression during an in vitro response of human B lymphocytes: Kinetics of B cell tumor necrosis factor a, interleukin (IL)6, IL-10, and transforming growth factor (3, mRNAs. J Exp Med 178: 521–528
Hata H, Xiao H, Petrucci MT, Woodliff J, Chang R, Epstein J (1993) Interleukin-6 gene expression in multiple myeloma: A characteristic of immature tumor cells. Blood 81: 3357–3364
Jelinek DF, Ahmann GJ, Greipp PR, Jalal SM, Westendorf JJ, Katzmann JA, Kyle RA, Lust JA (1993) Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: Clinical implications. Cane Res 53: 5320–5327
Westendorf JJ, Ahmann GJ, Armitage RJ, Spriggs MK, Lust JA, Greipp PR, Katzmann JA, Jelinek DF (1994) CD40 expression in malignant plasma cells: Role in stimulation of autocrine IL-6 secretion by a human myeloma cell line. J Immunol 152: 117–128
Banchereau J, Baza F, Blanchard D, Briere F, Galizzi JP, van Kooten C, Liu YJ, Rousset F, Saeland S (1994) The CD40 antigen and its ligand. Annu Rev Immunol 12: 881–922
Clark EA, Shu G (1990) Association between IL-6 and CD40 signaling. J Immunol 145: 1400–1406
O’Reilly DR, Miller LK, Luckow VA (1994) Baculovirus expression vectors, a laboratory manual. Oxford University Press, New York
Brian AA (1988) Membrane isolated procedure stimulation of B-cell proliferation by membrane-associated molecules from activated T cells. Proc Natl Acad Sci USA 85: 564–568
Paulie S, Ehlin-Henriksson B, Mellstedt H, Kobo H, Ben-Aissa H, Perlmann P (1985) A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes. Cane Immunol Immunother 20: 23–28
Ling NR, MacLennan ICM, Mason D (1987) B-cell and plasma cell antigens: New previously defined clusters. In: McMichael AJ (ed) Leucocyte typing III. Oxford University Press, Oxford, pp 302–335
Terstappen LWMM, Johnsen S, Segers-Nolton IMJ, Loken MR (1990) Identification and characterization of plasma cells in normal bone marrow by high-resolution flow cytometry. Blood 76: 1739–1747
Klein B, Zhang XG, Jourdan M, Content J, Moussiau F, Aarden L, Bataille R (1989) Paracrine but not autocrine regulation of myeloma cell growth and differentiation by interleukin 6. Blood 73: 517–526
Kyle RA, Lust JA (1989) Monoclonal gammopathies of undetermined significance. Sem Hematol 26: 176–200
Santhanum U, Ray A, Sehgal PB (1991) Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci USA 88: 7605–7609
Durie BGM (1992) Cellular and molecular genetic features of myeloma and related disorders. Hem/One Clin N Amer 6: 463–477
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Westendorf, J.J. et al. (1995). Molecular and Biological Role of CD40 in Multiple Myeloma. In: Potter, M., Melchers, F. (eds) Mechanisms in B-Cell Neoplasia 1994. Current Topics in Microbiology and Immunology, vol 194. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79275-5_9
Download citation
DOI: https://doi.org/10.1007/978-3-642-79275-5_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-79277-9
Online ISBN: 978-3-642-79275-5
eBook Packages: Springer Book Archive